Price Chart

Profile

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
URL https://www.atai.life
Investor Relations URL https://ir.atai.com/
HQ State/Province N/A
Sector Health Care
Industry Pharmaceuticals
Next Earnings Release Aug. 13, 2025 (est.)
Last Earnings Release May. 14, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
URL https://www.atai.life
Investor Relations URL https://ir.atai.com/
HQ State/Province N/A
Sector Health Care
Industry Pharmaceuticals
Next Earnings Release Aug. 13, 2025 (est.)
Last Earnings Release May. 14, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A